Managers / Q4 2019 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $293M in U.S.-listed holdings across 12 positions for Q4 2019.
Its largest position, UTHR, represents 13.9% of the portfolio.
Compared with Q3 2019, the fund opened 4 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 89.8% · $263M
- Other · 10.2% · $30M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| REGNREGENERON PHARMACEUTICALS | NEW | +104.4K | 104.4K | +$39M | $39M |
| TARO PHARMACEUTICAL INDUS | NEW | +339.8K | 339.8K | +$30M | $30M |
| ALKSALKERMES PLC | NEW | +905.1K | 905.1K | +$18M | $18M |
| ANABANAPTYSBIO INC | NEW | +440.4K | 440.4K | +$7M | $7M |
| ELANElanco Animal Health Inc | SOLD OUT | −892.6K | 0 | −$24M | $0 |
| AVNSAvanos Medical Inc | SOLD OUT | −59.4K | 0 | −$2M | $0 |
| GILDGILEAD SCIENCES INC | TRIMMED | −429.9K | 121.9K | −$27M | $8M |
| BIIBBIOGEN INC | TRIMMED | −66.8K | 109.9K | −$9M | $33M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 13.85% | $41M | 460.9K |
| 2 | REGNREGENERON PHARMACEUTICALShistory → | COM | 13.38% | $39M | 104.4K |
| 3 | MCKMCKESSON CORPhistory → | COM | 12.00% | $35M | 254.3K |
| 4 | ALXNALEXION PHARMACEUTICALS INChistory → | COM | 11.57% | $34M | 313.6K |
| 5 | BIIBBIOGEN INChistory → | COM | 11.13% | $33M | 109.9K |
| 6 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 10.32% | $30M | 489.4K |
| 7 | TARO PHARMACEUTICAL INDUS | COM | 10.20% | $30M | 339.8K |
| 8 | ALKSALKERMES PLChistory → | COM | 6.30% | $18M | 905.1K |
| 9 | RTI SURGICAL HDS INC | COM | 3.39% | $10M | 3.63M |
| 10 | INVACARE CORP | COM | 2.71% | $8M | 880.4K |
| 11 | GILDGILEAD SCIENCES INChistory → | COM | 2.70% | $8M | 121.9K |
| 12 | ANABANAPTYSBIO INChistory → | COM | 2.44% | $7M | 440.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.